Notice Pursuant to the National Cooperative Research and Production Act of 1993-Biopharmaceutical Manufacturing Preparedness Consortium

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

January 2, 2026

Issuing agencies

Justice DepartmentAntitrust Division

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 1 (Friday, January 2, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 1 (Friday, January 2, 2026)]
[Notices]
[Pages 164-165]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-24165]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness 
Consortium

    Notice is hereby given that, on April 10, 2025, pursuant to section 
6(a) of the National Cooperative Research and

[[Page 165]]

Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''), 
Biopharmaceutical Manufacturing Preparedness Consortium (``BIOMAP-
CONSORTIUM'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing changes in 
its membership. The notifications were filed for the purpose of 
extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, CytoImmune Therapeutics, Inc., Duarte, CA; Ecolab, 
Inc., Philadelphia, PA; Evoworks Bio, Cambridge, MA; Sterling Wisconsin 
LLC, Germantown, WI; University of Louisiana at Lafayette, Lafayette, 
LA; 375Sciences, Summit Point, WV; Ambient Biosciences, Ann Arbor, MI; 
CODEXIS, Inc., Redwood City, CA; Jamison Case, Batesville, AR; WellPact 
LLC, Roaring Spring, PA; Advanced Sterilization Technology, Inc., 
Denver, CO; Grassroots Political Consulting LLC, Alexandria, VA; Neion 
Bio, Inc., New York, NY; Northern RNA, Inc., Calgary, CANADA; Ronawk, 
Inc., Overland Park, KS; Rozum Consulting, Newtown, PA; Continuity 
Pharma, West Lafayette, IN; General Therapeutics, Gaithersburg, MD; and 
Public Health Vaccines LLC, Cambridge, MA have been added as parties to 
this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and the BIOMAP-CONSORTIUM intends to 
file additional written notifications disclosing all changes in 
membership.
    On January 5, 2024, the BIOMAP-CONSORTIUM filed its original 
notification pursuant to section 6(a) of the Act. The Department of 
Justice published a notice in the Federal Register pursuant to section 
6(b) of the Act on April 16, 2024 (89 FR 26923).
    The last notification was filed with the Department on January 14, 
2025. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on February 28, 2025 (90 FR 10946).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2025-24165 Filed 12-31-25; 8:45 am]
BILLING CODE P


</pre></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on January 2, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.